Pharmassist achieves another grant by “Competitiveness, Entrepreneurship and Innovation” (EPAnEK) for expanding its R&D activities to Drug Safety/Clinical field

Pharmassist has been subsidized by the “Competitiveness, Entrepreneurship and Innovation” (EPAnEK) Operational Program for R&D activities, regarding the development and implementation of an IT platform towards the identification, investigation and management of candidate Adverse Drug Reaction (ADR) signals, and its integration within clinical context. This PVClinical platform (https://pvclinical-project.eu/) is based on the post-market drug safety surveillance and focuses on the unified and holistic integration of data sources such as spontaneous reporting systems, electronic health records, the literature, Web search logs, and social media. The ultimate objective is the smooth integration of this tool into clinical environments, reinforcing drug safety in everyday clinical practice, but also within the pharma industry in studying drug safety issues, as well as in drug monitoring organizations. Through this project, Pharmassist enhances its dynamic within the international CRO market. Pharmassist’s total budget has reached the amount of 252.000€ of an overall project budget of 917.200€. 

This research has been co‐financed by the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH – CREATE – INNOVATE (project code: T1RCI-03789).